Cardinal Health Forecasts $10 EPS and $50B Specialty Revenues by Fiscal Year 2026

Cardinal Health Projects Strong Growth in Specialty Revenues and EPS for Fiscal Year 2026

Cardinal Health has recently updated its fiscal year 2026 outlook, raising its expectations for non-GAAP diluted earnings per share (EPS) to a minimum of $10.00, up from a previous estimate of $9.65 to $9.85. This upward revision underscores the company's robust performance across its diverse business segments, particularly in specialty distribution. The anticipated growth reflects Cardinal Health's strategic focus on enhancing its service offerings and leveraging emerging opportunities in the healthcare market. The company's commitment to innovation and patient care is evident in its efforts to expand its capabilities, which positions it favorably for sustained financial success.

In addition to the EPS forecast, Cardinal Health projects that its Specialty revenues will surpass $50 billion in fiscal 2026, reflecting an impressive compounded annual growth rate (CAGR) of 16% over the next three years. This surge is attributed to heightened demand in specialty distribution, as well as significant growth within the BioPharma Solutions segment, which is expected to increase by over 30%. A key factor in this success is the Sonexus™ Access and Patient Support business, which has recently transitioned major programs to its platform, including the Dupixent My Way initiative for Sanofi and Regeneron. These developments not only bolster Cardinal Health’s market position but also enhance its ability to support patients and healthcare providers in navigating complex therapeutic landscapes.

Moreover, Cardinal Health demonstrates its agility in responding to regulatory changes, such as those related to the 2026 Medicare Drug Price Negotiation Program. The company has effectively managed the transition of its manufacturer distribution service agreements to ensure compliance while maintaining service quality for its branded pharmaceutical products. In a bid to further elevate patient care, Cardinal Health has launched the innovative ContinuCare™ Pathway program, which simplifies diabetes supply management for pharmacies and patients. The establishment of a strategic partnership with Publix Super Markets Inc. further exemplifies the company's commitment to improving healthcare access and outcomes.

In addition to these strategic initiatives, Cardinal Health’s CEO Jason Hollar expresses confidence in the company’s growth trajectory, emphasizing the positive impact of ongoing investments in product innovation and technology. The upcoming second quarter earnings call, scheduled for February 5, 2026, is expected to provide further insights into the company’s strategic plans and operational performance as it continues to navigate the dynamic healthcare landscape. As Cardinal Health builds on its achievements, stakeholders remain attentive to the unfolding developments that will shape its future direction in the healthcare sector.